Astera Labs, Inc. (NASDAQ:ALAB – Get Free Report) CEO Jitendra Mohan sold 173,366 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $110.12, for a total value of $19,091,063.92. Following the transaction, the chief executive officer now directly owns 600,000 shares of the company’s stock, valued at $66,072,000. The trade was a 22.42 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Jitendra Mohan also recently made the following trade(s):
- On Thursday, November 21st, Jitendra Mohan sold 171,064 shares of Astera Labs stock. The shares were sold at an average price of $103.53, for a total value of $17,710,255.92.
- On Friday, October 11th, Jitendra Mohan sold 47,667 shares of Astera Labs stock. The stock was sold at an average price of $70.26, for a total value of $3,349,083.42.
Astera Labs Price Performance
ALAB stock traded down $5.88 on Wednesday, reaching $99.60. The company had a trading volume of 5,209,101 shares, compared to its average volume of 3,190,953. Astera Labs, Inc. has a 1 year low of $36.22 and a 1 year high of $113.85. The company’s fifty day moving average is $72.05 and its 200 day moving average is $60.30.
Institutional Trading of Astera Labs
Institutional investors and hedge funds have recently made changes to their positions in the stock. Hollencrest Capital Management purchased a new stake in shares of Astera Labs in the third quarter valued at $26,000. US Bancorp DE acquired a new stake in Astera Labs during the third quarter worth about $46,000. First Horizon Advisors Inc. bought a new position in Astera Labs during the third quarter worth about $49,000. Allworth Financial LP lifted its stake in Astera Labs by 445.5% during the third quarter. Allworth Financial LP now owns 1,091 shares of the company’s stock worth $57,000 after purchasing an additional 891 shares during the period. Finally, Amalgamated Bank bought a new position in shares of Astera Labs in the second quarter valued at approximately $74,000.
Wall Street Analyst Weigh In
A number of equities research analysts have issued reports on ALAB shares. JPMorgan Chase & Co. boosted their price target on Astera Labs from $70.00 to $110.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Evercore ISI lowered their price target on Astera Labs from $98.00 to $80.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. Stifel Nicolaus upped their price objective on Astera Labs from $80.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft boosted their target price on Astera Labs from $60.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Finally, Citigroup initiated coverage on Astera Labs in a research report on Monday, November 18th. They issued a “buy” rating and a $120.00 price objective on the stock. Twelve research analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $94.67.
View Our Latest Report on Astera Labs
Astera Labs Company Profile
Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.
Featured Stories
- Five stocks we like better than Astera Labs
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- ESG Stocks, What Investors Should Know
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- How to Use Stock Screeners to Find Stocks
- 2 Generic Drug Stocks Ready to Surge in 2025
Receive News & Ratings for Astera Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astera Labs and related companies with MarketBeat.com's FREE daily email newsletter.